<?xml version="1.0" encoding="UTF-8"?><rss xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:content="http://purl.org/rss/1.0/modules/content/" xmlns:atom="http://www.w3.org/2005/Atom" version="2.0" xmlns:cc="http://cyber.law.harvard.edu/rss/creativeCommonsRssModule.html">
    <channel>
        <title><![CDATA[PLOS Synbio Field Reports - Medium]]></title>
        <description><![CDATA[Collaborative Blogging by the PLOS Synthetic Biology Community - Medium]]></description>
        <link>https://medium.com/plos-synbio-field-reports?source=rss----acfecace5654---4</link>
        <image>
            <url>https://cdn-images-1.medium.com/proxy/1*TGH72Nnw24QL3iV9IOm4VA.png</url>
            <title>PLOS Synbio Field Reports - Medium</title>
            <link>https://medium.com/plos-synbio-field-reports?source=rss----acfecace5654---4</link>
        </image>
        <generator>Medium</generator>
        <lastBuildDate>Thu, 19 Nov 2026 06:00:06 GMT</lastBuildDate>
        <atom:link href="https://medium.com/feed/plos-synbio-field-reports" rel="self" type="application/rss+xml"/>
        <webMaster><![CDATA[yourfriends@medium.com]]></webMaster>
        <atom:link href="http://medium.superfeedr.com/" rel="hub"/>
        <item>
            <title><![CDATA[An Introduction to Start-Ups in Synthetic Biology]]></title>
            <link>https://medium.com/plos-synbio-field-reports/an-introduction-to-start-ups-in-synthetic-biology-7417888e8c1b?source=rss----acfecace5654---4</link>
            <guid isPermaLink="false">https://medium.com/p/7417888e8c1b</guid>
            <category><![CDATA[science]]></category>
            <category><![CDATA[health]]></category>
            <dc:creator><![CDATA[Aditya Kunjapur]]></dc:creator>
            <pubDate>Tue, 08 Sep 2015 16:00:00 GMT</pubDate>
            <atom:updated>2015-09-17T11:55:02.141Z</atom:updated>
            <content:encoded><![CDATA[<figure><img alt="" src="https://cdn-images-1.medium.com/max/1024/1*6L4qYrZsZ6-g8pz9AJALtA.jpeg" /></figure><h4>When did you first hear the phrase “synthetic biology”? Was it many years ago, or did it just happen when you clicked on this blog?</h4><p>Synthetic biology — or SynBio — involves the engineering of biological systems to create useful products or functions through thoughtful tinkering with DNA. Commercial applications span several industries: energy, chemicals, materials, pharma, food, agriculture, diagnostics, probiotics, antibiotics, and gene therapy — just to name a few. According to <a href="https://www.alliedmarketresearch.com/synthetic-biology-market">one analysis</a> from 2014, the global SynBio market was valued at $3.0 billion in 2013 and is estimated to reach $38.7 billion by 2020.</p><p>I first heard about SynBio in 2009 and am now a researcher in this field. In this post, I will describe a representative set of SynBio start-ups alongside a personal narrative of my expanding interest in the field. Despite what little I know, I will also speculate on what may lie ahead. If you are a fan of science, a SynBio student or practitioner, or an investor in start-ups, then this post is especially for you.</p><h4><strong>Fuels and SynBio Start-ups v1.0</strong></h4><p>In 2004, I wrote to the Houston Museum of Natural Science about my desire to help cure what I called “The Black Plague of Black Gold.” I was a high school junior in the Energy Corridor of West Houston and wanted to help end our reliance on petroleum.</p><p>Five years later, I worked part-time in a lab at the University of Texas cultivating strains of algae that naturally accumulate oil. We wanted to harvest the oil as a potential biofuel, and I wondered how we could coax the algae into producing more of it. I was a chemical engineering major and did not know much about biology. But then I heard about a start-up that was doing “synthetic biology” to make renewable fuels. The six year old company was <a href="https://amyris.com/our-company/">Amyris</a>.</p><p>Amyris genetically engineers yeast to produce a chemical called farnesene from sugar. Farnesene can be used as biodiesel or as jet fuel. I was amazed at the time to see that they also engineer yeast to produce artemisinic acid, an immediate precursor to an antimalarial drug. Natural yeast strains do not contain farnesene, artemisinic acid, or anything chemically similar.</p><p>Over the next few weeks, I found out about other start-ups that engineer microbes ranging from algae to <em>E. coli</em> in order to produce biofuels from sugar. Among these companies are <a href="http://www.syntheticgenomics.com/ourbusiness.html">Synthetic Genomics</a>, <a href="http://solazyme.com/company/?lang=en">Solazyme</a>, <a href="http://www.jouleunlimited.com/about-joule">Joule Unlimited</a>, and LS9 (now <a href="http://www.regi.com/news/2014/01/22/renewable-energy-group-enters-industrial-biotech-acquisition-ls9">REG Life Sciences</a>).</p><p>SynBio fuel efforts seemed to receive validation in the marketplace. For example, in June 2009, oil and gas giant ExxonMobil <a href="http://www.nytimes.com/2009/07/14/business/energy-environment/14fuel.html?pagewanted=all">invested $300 million</a> into Synthetic Genomics as part of an R&amp;D partnership to develop biofuels. Amyris became <a href="http://www.reuters.com/article/2010/09/28/amyris-ipo-idUSN2726449120100928">publicly traded</a> the following year.</p><h4><strong>Higher Value Products and SynBio Start-ups v2.0</strong></h4><p>The apparent commercial success of SynBio fuel start-ups influenced my decision to join a SynBio lab in graduate school in early 2011. Once there, I realized that microbes could be engineered to produce essentially any of the numerous products that are ordinarily derived from petroleum. And in order to provide a path towards complete independence from petroleum, it is important to find sustainable routes to make these products in addition to fuels. The use of microbes that are engineered to efficiently convert renewable inputs to products at high yields is an elegant strategy for many products. However, based on rough economic considerations, I gradually began to question whether fuels were practical targets for SynBio start-ups.</p><p>The “carbon value chain” is a concept that categorizes carbon-containing products based on their price per mass. Although other variables, such as market size and maximum theoretical yield, are important, the carbon value chain offers quick insight into the largest margins that SynBio companies can realize on processes that generally all use sugar ($0.25-$0.50/kg) as an input. The image below depicts approximate current bulk prices for rough categories of potential SynBio products.</p><figure><img alt="" src="https://cdn-images-1.medium.com/max/1024/1*IJg7UfJC0F0zIRkyVSV_xg.jpeg" /></figure><p>Some SynBio start-ups originally focused on producing chemicals with higher value than fuels. For example, <a href="http://www.myriant.com/our-company/index.cfm">Myriant Technologies</a> and <a href="http://lygos.com/innovation/">Lygos</a> produce succinic acid (historically $3–5/kg) or malonic acid (historically $20–30/kg), respectively. <a href="http://www.genomatica.com/about/">Genomatica</a> uses engineered strains to produce 1,4-butanediol, butadiene, and nylon intermediates. However, most SynBio start-ups, including fuel start-ups mentioned earlier, <a href="http://www.nature.com/news/synthetic-biology-firms-shift-focus-1.14602">recently pivoted</a> towards higher value chemicals to stay in business.</p><p>Some start-ups are aiming for sectors within higher value chemicals where may be consumer preference for biologically-derived goods, such as in textiles and flavors. <a href="http://boltthreads.com/about-us/">Bolt Threads</a> uses yeast to produce silk and high performance fabrics, and <a href="http://www.evolva.com/about-us/mission-strategy">Evolva</a> engineers yeast to produce several flavors and fragrances. <a href="http://ginkgobioworks.com/">Ginkgo Bioworks</a> and <a href="http://zymergen.com/about.php">Zymergen</a> are two other companies that intend to produce flavors and fragrances but are more oriented towards building automated pipelines for industrial strain development. Many of these companies partner with other entities that grow the strains at commercial scale and purify the product.</p><p>In light of these industrial trends, my graduate research dabbled in improving biofuel production but had greater emphasis on engineering <em>E. coli </em>for production of <a href="http://pubs.acs.org/doi/abs/10.1021/ja506664a">higher value products</a>. Some of my findings had clear commercial implications in the flavors and fragrances sector, where a surprisingly large percentage of products come from petroleum, including most vanilla in the market.</p><h4><strong>SynBio Start-ups Taking on Other Challenges</strong></h4><p>The discipline of chemical engineering focuses on developing or improving processes that produce chemicals. Despite having that background, I have been interested in the new generation of SynBio start-ups that are pursuing commercial applications beyond chemical manufacturing. For example, <a href="http://sample6.com/company/">Sample6</a> brings SynBio into the realm of food safety by offering advanced detection of pathogens. <a href="http://synlogictx.com/#about">SynLogic</a> develops therapeutic microbes for patients with inflammation and metabolic diseases. <a href="http://synthorx.com/about/">Synthorx</a> produces novel proteins for life science applications by expanding the genetic alphabet.</p><p>Genome editing is an area of SynBio that has received more publicity lately. Breakthroughs achieved by the discovery and development of a gene editing technology known as CRISPR/Cas9 have resulted in start-ups such as <a href="http://editasmedicine.com/about.php">Editas Medicine</a>, <a href="http://cariboubio.com/">Caribou Biosciences</a>, <a href="http://intelliatx.com/">Intellia Therapeutics</a>, and <a href="http://crisprtx.com/overview/">CRISPR Therapeutics</a>. All are geared towards developing treatments for genetic diseases.</p><p>SynBio is also advancing the development of alternatives to animal products. <a href="http://signup.pembient.com/">Pembient</a> seeks to reduce poaching by fabricating rare wildlife products such as rhino horn and elephant ivory. <a href="http://www.modernmeadow.com/#home">Modern Meadow</a> plans to use tissue engineering and 3D printing to fabricate leather and meat. <a href="http://www.muufri.com/">Muufri</a> plans to make animal-free milk and <a href="http://www.clarafoods.com/">Clara Foods</a> plans to make animal-free eggs. As a lifelong vegetarian due to animal welfare concerns, I find the objectives of these companies just as compelling as reduction of our dependence on petroleum or treatment of genetic diseases.</p><p>Given the wide range of commercial possibilities for SynBio, I sought to diversify my research experiences further by doing a post-doc in a genetics lab at a medical school. My current goal is to briefly step back from any particular application and instead focus more on the development of methods and tools that may later find use in several applications.</p><h4><strong>Pathways Ahead for SynBio Start-ups</strong></h4><p>Thus far in 2015, several SynBio start-ups have made headlines after earning investments from venture capital firms. For example:</p><p>· Bolt Threads: <a href="http://techcrunch.com/2015/06/04/spiderpants/">$32 million, Series B</a></p><p>· Caribou Biosciences: <a href="http://cariboubio.com/media/">$11 million, Series A</a></p><p>· Editas Medicine: <a href="http://techcrunch.com/2015/06/04/spiderpants/">$120 million, Series B</a></p><p>· Ginkgo Bioworks: <a href="http://techcrunch.com/2015/07/23/ginkgo-bioworks-takes-on-zymergen-with-45-million-in-series-b-funding/">$45 million, Series B</a></p><p>· Twist Biosciences: <a href="http://synbiobeta.com/twist-bioscience-closes-37-million-series/">$37 million, Series C</a></p><p>· Zymergen: <a href="http://techcrunch.com/2015/06/16/with-44-million-in-funding-biotech-startup-zymergen-is-buying-up-robots-to-mass-produce-materials-from-microbes/">$42 million, Series A</a></p><p>While large fundraising totals seem rosy, higher valuations may lead to more expectations from investors (the HBO Series <em>Silicon Valley</em> portrays this nicely). In addition to high expectations, several challenges lie ahead for SynBio start-ups. Prices of most petroleum-based products may drop now that crude oil prices have plummeted from $100/barrel to roughly $40/barrel. In the specialty chemicals arena, lots of small fragmented markets dominated by incumbents await new players. In food additives, consumer acceptance is an issue. In healthcare, new therapeutic modalities face regulatory hurdles.</p><p>Yet the upsides and opportunities seem to be bigger. Only a small fraction of the diversity of life on Earth has been genetically cataloged and even model organisms have significant room for functional annotation and for redesign to eliminate many unnecessary traits. Given this state, the field is ripe with potential for revolutionary discoveries of natural tools and products. The prices of DNA synthesis and sequencing declined at greater than exponential rates during the last decade and are expected to continue to do so. Commercial knowhow in SynBio is vastly increasing. Advances in machine learning, robotics, automation, and microfluidics all stand to decrease costs and time required for the design-build-test-learn cycle.</p><p>Now that start-ups have raised so much money, will the rate of innovation in the private sector start to outpace that of academic labs? Although start-up labs seem to have a lot more automation than academic labs, I personally think it will take many more years before they become more innovative than academia given the potential of basic science research to suddenly result in groundbreaking and commercially relevant advancements (e.g. CRISPR/Cas9), as well as the difficulty for start-ups to devote resources to non-essential projects with long time-frames and high risks. My feeling of contentment in an academic setting is influenced by this opinion.</p><p>Overall, SynBio is an incredibly exciting field to be a part of because of its potential to address diverse societal problems and because our ability to engineer biological systems has so much room for improvement. Flush with capital and lessons from fuels, SynBio start-ups are uniquely poised at this moment to execute on their grand ideas. It will be fascinating to see what other SynBio start-ups emerge and how all of them begin to change the world, and I look forward to assisting them in some capacity when the time is right.</p><p>Your turn: If you are a student or practitioner of SynBio, how did you get interested in this field?</p><p>Many SynBio start-ups were not mentioned in this post. Do you work for one of them? If so, tell us about them in the comments section.</p><p><em>Aditya Kunjapur is currently a post-doctoral research fellow in the laboratory of Dr. George Church at Harvard Medical School. He received his Ph.D. in Chemical Engineering from the Massachusetts Institute of Technology in June 2015. All opinions stated in this post are his own views and not representative of any institutions. If you enjoyed this post, you can follow him on </em><a href="https://twitter.com/kunjapur"><em>Twitter</em></a><em>.</em></p><p><strong><em>Declarations</em></strong><em>: The author has no affiliation with, involvement in, or financial interest in any of the companies included in this post.</em></p><img src="https://medium.com/_/stat?event=post.clientViewed&referrerSource=full_rss&postId=7417888e8c1b" width="1" height="1" alt=""><hr><p><a href="https://medium.com/plos-synbio-field-reports/an-introduction-to-start-ups-in-synthetic-biology-7417888e8c1b">An Introduction to Start-Ups in Synthetic Biology</a> was originally published in <a href="https://medium.com/plos-synbio-field-reports">PLOS Synbio Field Reports</a> on Medium, where people are continuing the conversation by highlighting and responding to this story.</p>]]></content:encoded>
        </item>
        <item>
            <title><![CDATA[How to better control or eradicate deadly infections using transgenesis or genome editing…]]></title>
            <link>https://medium.com/plos-synbio-field-reports/how-to-better-control-or-eradicate-deadly-infections-using-transgenesis-or-genome-editing-45a004f76a3?source=rss----acfecace5654---4</link>
            <guid isPermaLink="false">https://medium.com/p/45a004f76a3</guid>
            <category><![CDATA[mosquito]]></category>
            <category><![CDATA[genetics]]></category>
            <category><![CDATA[crispr]]></category>
            <dc:creator><![CDATA[Gaetan Burgio]]></dc:creator>
            <pubDate>Wed, 26 Aug 2015 12:40:35 GMT</pubDate>
            <atom:updated>2015-08-26T16:20:37.049Z</atom:updated>
            <content:encoded><![CDATA[<figure><img alt="" src="https://cdn-images-1.medium.com/max/1024/1*iVA1RTgXl0ShqpB3oC_tyg.jpeg" /></figure><h2>How to better control or eradicate deadly infections using transgenesis or genome editing technologies?</h2><p><em>Deadly infectious diseases, such as those transmitted through mosquitoes, are a huge threat to the human population. The rapid pace in the development of transgenesis technologies and genome editing over the last few years have raised many hopes, but also given birth to many fears.</em></p><h4><strong>Mosquito borne diseases: threats to human health</strong></h4><p>Mosquitoes transmit many infections, including malaria, dengue, yellow fever and chikunguna. These mosquito-borne diseases affect millions of people worldwide and are a huge cost burden for populations living in these endemic areas. It is a matter of urgency that new treatments are found to improve the quality of life, and to save lives. Unfortunately there are to date no efficient vaccines or drug treatments available to cure these deadly diseases. Preventive strategies such as bed-nets or insecticides are the mainstay for control and prevention of these diseases. However, insecticide resistance is developing at an alarming pace preventing any hope of controlling or curing these diseases. Recently however, the rapid developments in the genetic technologies such as transgenesis or genome editing have raised hope and confidence in combatting and controlling these diseases.</p><h4><strong>Mutating mosquitoes: A promising avenue to control these diseases.</strong></h4><p>Way before the rise of genetic technologies, back in the 1930’s, it was thought that these diseases could be controlled by releasing large numbers males mosquitoes sterilized with high dose irradiation. Native females that mated with sterile males would not produce any viable eggs. The Sterile Insect Technique (SIT) has proven successful in controlling pest such as fruit flies, however the success rate is variable due to the decreased fitness of the sterile males, competition from other males or immigration of pre-mated females.</p><p>With the discovery of gene knockout, PiggyBac, transposon mutagenesis, or, more recently RNA interference, the success of SIT technologies has significantly increased. This improvement has led to better disease control due to the prevention of the development of the mosquito larva or due to the exertion of a killing effect against the pathogens. Using various release strategies such as fogging, vehicle release or more recently, sustained release of transgenic male mosquitoes, attempts to control mosquito-borne diseases has had variable success. For instance, a few attempts have been made to control mosquitoes responsible for dengue fever using transgenesis strategies. Insects carrying a dominant lethal mutation (RIDL) were released in large numbers in the field. In one instance, the RIDL strain OX513A, a late acting lethal mutation at pup stage of the larval development, has proven successful in well-defined and small areas endemic for dengue fever in South America. However this strategy is not suitable for a large release of transgenic mosquitoes as it does not fully suppress the population already present and not subject to transgenic alteration.</p><h4><strong>The rise of genome editing technologies.</strong></h4><p>Recently, Genome editing technologies such as Zinc-Finger nucleases or Transcription Activator-Like Effector (TALE) have increased the flexibility and ease of generating transgenic mosquitoes. While multiple transgenic strains have been created, none to date have been released in the field. Recently, the CRISPR/Cas9 (Clustered Regularly Interspaced Short Palindromic Repeats) mediated genome editing has considerably facilitated the generation of transgenic mosquitoes by genome manipulation. Recent experiments in flies have pushed the boundaries of the technology to its limits by creating mutations and transmitting almost 100% of the genetic alterations across to the next generation. This ‘chain reaction’ or ‘gene drive’ strategy could be use to rapidly spread mutant genes without having to sequentially release the insects in the field. In a very short period of time, the desired mutation can spread rapidly through the population and become highly prevalent in all the targeted vector population. By targeting the vector, this technique has shown it can lead to the eradication of the disease. This ‘gene drive’ strategy has the promising potential of curing mosquito-borne diseases such dengue, malaria or yellow fever.</p><h4><strong>Ethical and ecological challenges</strong></h4><p>The latest technologies of using CRISPR/Cas9 genome editing and, in general, transgenesis strategies in mosquitoes, whether combined or not with the use of the ‘gene drive’ technology, has raised the possibility of the eradication of mosquito-borne diseases. However, there are serious ethical and ecological challenges to consider before adopting these strategies. Firstly, a successful vector control program relies on the fitness of the mutated vectors, the nature of the gene targeted and the vector release protocol. Additionally, sterile males would have to compete with wild males in a genetically diverse mosquito population. Worryingly, as well as PiggyBac transposon mutagenesis, genome-editing strategy creates off-target effects that could spread into the targeted population and to another species and would have the potential to considerably modify the genome of a non-targeted population. Additionally, there is always a risk of the lack of biocontainment and escape from CRISPR/Cas9 edited mosquitoes leading to a ‘chain reaction’ in the wild population. The fast pace in the development of genome editing technologies and ‘gene drive’ shows exciting potential, but the scientific community has also expressed concerns and fears about the rapid adoption of this technology. Discussions between researchers, regulatory agencies, ethicists, philosophers and the public must occur to ensure that the community is well informed of the risks, benefits, and limitations of genome editing and gene drive technologies.</p><p>There are many reasons to hope that deadly infectious mosquitoes-borne diseases will be controlled using transgenesis and genome editing technologies. To ensure success of these strategies, all stakeholders, including the public, ethicists, researchers, agencies, and patients, must participate be fully informed of the advantages and disadvantages of using these exciting new technological developments.</p><img src="https://medium.com/_/stat?event=post.clientViewed&referrerSource=full_rss&postId=45a004f76a3" width="1" height="1" alt=""><hr><p><a href="https://medium.com/plos-synbio-field-reports/how-to-better-control-or-eradicate-deadly-infections-using-transgenesis-or-genome-editing-45a004f76a3">How to better control or eradicate deadly infections using transgenesis or genome editing…</a> was originally published in <a href="https://medium.com/plos-synbio-field-reports">PLOS Synbio Field Reports</a> on Medium, where people are continuing the conversation by highlighting and responding to this story.</p>]]></content:encoded>
        </item>
        <item>
            <title><![CDATA[12 Months in Synthetic Biology]]></title>
            <link>https://medium.com/plos-synbio-field-reports/12-months-in-synthetic-biology-41d7159a5b4b?source=rss----acfecace5654---4</link>
            <guid isPermaLink="false">https://medium.com/p/41d7159a5b4b</guid>
            <category><![CDATA[science-communication]]></category>
            <category><![CDATA[science]]></category>
            <category><![CDATA[synthetic-biology]]></category>
            <dc:creator><![CDATA[David Shifrin]]></dc:creator>
            <pubDate>Wed, 19 Aug 2015 14:56:23 GMT</pubDate>
            <atom:updated>2015-08-19T15:06:00.061Z</atom:updated>
            <content:encoded><![CDATA[<figure><img alt="" src="https://cdn-images-1.medium.com/max/1024/1*KKbAoOsuk-AeMH0ADHMIzg.png" /></figure><h4>A brief review, a thank you, and an opportunity</h4><p>Science hit an inflection point somewhere in the past 10–15 years. We reached a point where all (or at many) of the pieces that go into discovery — these include hard technologies like computing power, light microscopy, techniques for manipulating DNA, and 3D printing, as well as conceptual pieces like the realization that “junk” DNA isn’t junk — actually work pretty well. That means they can be used together to learn more, faster. Interdisciplinary research, and all that. In the same way that synthetic biologists combine and recombine functional genetic parts into novel biological systems, scientists as a whole combine and recombine all the tools of research to make new discoveries. The solid base of technology and knowledge that now exists has significantly increased the slope of the line of scientific discovery. We’ve gone from “that’s science fiction,” to, “no, seriously, it can be done. And we’re doing it.”</p><p>Focusing down a little bit, the past year in synthetic biology has been a wild and dramatic time. In other way, of course, it’s just been a normal 12 months in which the steady march of scientific progress has continued. It’s silly to overstate any given moment in time just to try and make a blog post a little more dramatic (who would do that!?). But… it is worth looking at everything that has happened since the middle of last year and appreciating what has actually been accomplished. We talk a lot about the future — how much science and tech can do/will be able to do for humanity and nature — but let’s not forget to look back occasionally.</p><p>Give me a minute here, and then I’ll explain why I’m getting all nostalgic. First, though, here is a small sample of things from the world of synthetic biology that we’ve taken note of since last August:</p><ul><li>iGEM: More participants, more parts, and better parts than ever before. The next generation of scientists is stepping up, and they don’t believe in “can’t.” Each year the participants take one more incremental step towards highly functional products for use in many different industries, all built with synthetic biology. Other prominent programs, such as Y Combinator, have been moving into biotech as well.</li><li>Indie Bio: The unique bio-accelerator introduced its first class of 11 startup biotech companies. The Indie Bio team isn’t just trying tweak biotech at the margins, but to bring big new ideas to market that will “solve humanity’s most pressing problems.”</li><li>Biohack spaces: Citizen science labs and biohack spaces aren’t new, but they have been gaining more attention and buy-in, both from the public and the scientific community. The word “grassroots” is nothing if not a buzzword these days, but biohacking really does fit the term. People who have an idea and a desire to make it work show up, collaborate, and simply try new things. Community labs are raising the scientific literacy of society while also providing the resources for novel ideas to come to light.</li><li><a href="http://www.telegraph.co.uk/news/science/science-news/11432058/Three-parent-babies-House-of-Lords-approves-law-despite-fears-children-could-be-sterile.html">Three-parent babies</a>: The ethics surrounding the application of synthetic biology are complex and hotly debated (and rightly so). Issues like gene editing, resurrecting extinct species, and biowarfare are all being hashed out by scientists, the public, and policy makers around the world. These discussions represent an incredible opportunity for scientists to engage with other stakeholders (i.e., everyone) and have real conversations about what these new technologies mean for society.</li><li>CRISPR: If the gene editing technique was a big deal a year ago, well, I don’t need to explain to you where it is now. It’s gone from being a valuable tool in research labs, to being <em>the thing</em> that everyone — inside and outside of science — is talking about. And I really do mean everyone, from <em>Radiolab</em> to the big news magazines to activist websites. Several companies have popped up in the past year focused solely on developing and applying CRISPR. I remember being amazed at how quickly Fire and Mello received their Nobel for discovering RNA interference (8 years). The countdown is on, but is it really going to take that long for Jennifer Doudna to end up in first class on a flight to Stockholm?</li><li>The human side of tech: The suicide of Cambrian Genomics founder Austen Heinz was an awful lesson (one of far too many) of the toll that science and business can take on those involved. For all the time we spend thinking about hard technology, we can’t forget about the emotional, mental, and physical challenges so many innovators deal with.</li></ul><p>I’ll stop there and get to the main point, which I promise won’t take another 750 words.</p><p>At the end of August, I will be leaving my post as co-editor of the PLOS Synthetic Biology Community. It has been a blast. Like, really, a lot of fun. I’m a cell biologist by training, and the past year has provided me an incredible opportunity to dig into this bizarre and exciting world that combines principles from my field, with engineering, with computer science, with…you name it.</p><p>I have loved the Google Hangouts, the interviews, and the live tweeting. I have been challenged to think about science in new ways, and to consider more deeply the ethical and societal ramifications of what we scientists do in lab. I have truly enjoyed reading and editing all the contributions from the Community, especially those from students from around the world.</p><p>Thank you to everyone who has contributed, commented, tweeted, and read. The PLOS Synbio Community has grown over the past year, thank you for being part of that.</p><p>Of course, there is a lot more to come from this Community. Aakriti will continue managing the site and driving it forward. She has done an incredible job of soliciting contributions, editing, helping with our social media accounts, and writing her own pieces… all while juggling a crazy schedule of school and science-related travel.</p><p>With that in mind, we are looking for a new editor to come on board and help Aakriti. We’d be happy to talk to anyone involved in synthetic biology research, but we’re particularly interested in having a grad student or post-docs join the team. If you think you might like to get involved and want more information, please send a note to synbiocommunity@plos.org or tweet @PLOSSynbio. Even if you don’t want to be considered for the editor position but still want to contribute, drop us a note. This really is a community effort, so we’d love to have you involved. Lastly, if you have any questions/comments for me personally, send me a note at dshifrin@filamentcommunications.com or tweet @dshifrin.</p><p>Thanks again to PLOS and you all for a great 12 months!</p><p>Best,</p><p>David Shifrin</p><img src="https://medium.com/_/stat?event=post.clientViewed&referrerSource=full_rss&postId=41d7159a5b4b" width="1" height="1" alt=""><hr><p><a href="https://medium.com/plos-synbio-field-reports/12-months-in-synthetic-biology-41d7159a5b4b">12 Months in Synthetic Biology</a> was originally published in <a href="https://medium.com/plos-synbio-field-reports">PLOS Synbio Field Reports</a> on Medium, where people are continuing the conversation by highlighting and responding to this story.</p>]]></content:encoded>
        </item>
        <item>
            <title><![CDATA[Design + Biology]]></title>
            <link>https://medium.com/plos-synbio-field-reports/design-biology-3cf78f43bb29?source=rss----acfecace5654---4</link>
            <guid isPermaLink="false">https://medium.com/p/3cf78f43bb29</guid>
            <category><![CDATA[synthetic-biology]]></category>
            <category><![CDATA[design]]></category>
            <category><![CDATA[biology]]></category>
            <dc:creator><![CDATA[Aakriti Jain]]></dc:creator>
            <pubDate>Thu, 06 Aug 2015 14:38:35 GMT</pubDate>
            <atom:updated>2015-08-06T14:38:35.553Z</atom:updated>
            <content:encoded><![CDATA[<figure><img alt="" src="https://cdn-images-1.medium.com/max/750/1*f_s5dSCKEYncMUs8pDeSdQ.png" /><figcaption>Courtesy of syntheticbiology.org</figcaption></figure><p>Examples like Dr. J. Craig Venter’s minimal cell and Dr. Jay Keasling’s synthetic biology derived anti-malarial, artemisinin, all work towards a central goal: standardization and integration of design principles in biology. This has had two major implications on the direction that biological research today is taking. First, it has now become more important than ever to approach biology with a diverse and interdisciplinary toolbox, and second, the fusion of design in biology has necessitated rethinking of design principles to make sense with this novel biological medium.</p><p>Design is a methodology and a practice that utilizes many different materials, techniques, expertise, and values in order to accomplish a goal and fulfill a set of requirements. In contrast, traditional biology has been largely limited to focused biologists, working on studying specific intricacies in defined biological systems. The evolution of biology from an observational to a technological science has mandated an influx of scientists and engineers from varying disciplines to define the new frontiers of biology. From whole cell mathematical models, to rethinking DNA as biological circuitry and applying control theory to these circuits, we have, in a relatively short time, started to think about biology in ways that we may have previously thought impossible.</p><p>This direct imposition of design principles into biology may have come with a price; nearly a decade after synthetic biology was first defined, we have realized that trying to cram all the intricacies of biological systems into standardized parts and objects may not always work. Rethinking biology as an engineering science may require a rethinking of engineering design principles as well: a set of principles that represent a movement towards optimization and perfection. Biology, on the other hand, may not always be responsive to such ideals.</p><p>In fact, it may not be the teachings of design that mandate such a regularization of an irregular system. Design, on the other hand, is an intellectual process that yearns to understand the environment it is presented with and discover solutions to a problem in not only a <strong>human-</strong>, but also a <strong>system</strong>-<strong>centric</strong> way. Therefore, design principles could perhaps be better utilized to lead biological research in a direction that works with the chaotic nature of biology as opposed to against it.</p><h4><strong>Synthesizing Science and Design</strong></h4><p>The combination of these two fields can create platforms of discussion and investigation for scientists and designers alike. Design is a highly interdisciplinary field that necessitates the use and understanding of multiple technologies and thought processes in order to solve problems. Such an interdisciplinary approach to tackle biological questions can help scientists view their research through different perspectives.</p><p>Integration of design in biology has often been parallelized with the engineering design strategy that has been used and vulgarized in the computing industry. Modularization and standardization of parts, biological circuitry, comparison of the genetic code to binary and more all showcase how we are trying to industrialize biology in the same way that we industrialized information technology and electronics. However, this engineering design take on biology instinctively tries to diminish the seeming chaos and millions of years worth of evolved complexity present in biology in nature.</p><figure><img alt="" src="https://cdn-images-1.medium.com/max/464/1*GPCJokGxB06uZf1KOkIt1w.jpeg" /><figcaption>Harry Campbell Illustration</figcaption></figure><p>The reason for this is that we don’t fully understand, yet, the basic fundamentals of biology. We have established details on the central dogma; however, we can’t treat cells simply as empty factories for reactions. In order to design and exploit biological systems, we need to first appreciate the chaos. We have to understand that each system is slightly different, and that, in fact, there is a non-modularity that exists in the current state of biology. The biologist’s first job, therefore, ought to be to understand the system that he or she is working with at each level of abstraction from culture tubes to individual cells to individual enzymes, and perhaps even the molecules, and the electrons and protons that define each cellular molecule. We use design thinking, in this way, to ask questions about our systems, for example, questions about regulation in metabolic pathways, or directions and methods to drive evolution in a way that we can capitalize on, or creating more details and visualization on biological systems. In doing so, we can begin to better accomplish our human-centric goals in the form of creative applications that don’t ignore the inherent intricacies of biology, but rather use and benefit from them.</p><p>In <a href="http://www.academia.edu/2718507/Design_in_synthetic_biology">Adrien Mackenzie’s essay</a>, he discusses how “many existing definitions and characterizations of synthetic biology take at face value the claim that design can be done and is done according to principles. The fact that design is also an aggregate of practices, spanning a highly variable set of techniques, processes, materials, abstractions and sensations, and often standing on shifting economic and organizational ground is barely recognized.” In this thinking, a biologist that utilizes design principles should want to define systems that work <em>with</em> the biological environment as opposed to <em>on top of</em> an environment.</p><img src="https://medium.com/_/stat?event=post.clientViewed&referrerSource=full_rss&postId=3cf78f43bb29" width="1" height="1" alt=""><hr><p><a href="https://medium.com/plos-synbio-field-reports/design-biology-3cf78f43bb29">Design + Biology</a> was originally published in <a href="https://medium.com/plos-synbio-field-reports">PLOS Synbio Field Reports</a> on Medium, where people are continuing the conversation by highlighting and responding to this story.</p>]]></content:encoded>
        </item>
        <item>
            <title><![CDATA[Learning lessons and building Biotech 2.0]]></title>
            <link>https://medium.com/plos-synbio-field-reports/learning-lessons-and-building-biotech-2-0-553c06378387?source=rss----acfecace5654---4</link>
            <guid isPermaLink="false">https://medium.com/p/553c06378387</guid>
            <category><![CDATA[biotech]]></category>
            <category><![CDATA[fail-fast]]></category>
            <category><![CDATA[synthetic-biology]]></category>
            <dc:creator><![CDATA[Ron Shigeta]]></dc:creator>
            <pubDate>Thu, 30 Jul 2015 22:32:42 GMT</pubDate>
            <atom:updated>2015-07-30T22:32:42.052Z</atom:updated>
            <content:encoded><![CDATA[<h4><strong>The following post was contributed by Ron Shigeta and the team over at IndieBio, an exciting incubator/accelerator with locations in Cork, Ireland and San Francisco, CA. We love what they are doing to promote synthetic biology and help companies successfully commercialize incredible new technology. That said, it’s important to note that PLOS does not have a formal relationship with IndieBio or its startup tenants. Interested in learning more about IndieBio, or applying for their accelerator program? Check them out at </strong><a href="http://indie.bio/"><strong>Indie.Bio</strong></a></h4><figure><img alt="" src="https://cdn-images-1.medium.com/max/683/0*pLsSrcrQAhgIwVE2.jpg" /></figure><h3>Translational Science and Biotech 2.0</h3><p>IndieBio is a unique experiment to understand how to build biotech startups cheaper, faster and with a higher percentage of success. We built an accelerator that gives seed funding (now $250k) to each company and helps them transform projects into businesses. As CSO of IndieBio, I’ve had a unique look into <a href="http://synbio.plos.org/2015/02/20/accelerating-synbio-into-industry-indiebio/">a dozen biotech startups</a> going from minimal product to shipping and booking revenue. We have learned that an astonishing number of long-held beliefs about building biotech companies are simply no longer true. It’s a new class of biotechnology companies we’re calling Biotech 2.0.</p><h4>Here are some of the lessons we’ve learned:</h4><h3>Biotech 2.0 can sell to new markets</h3><p>The applications for both our current and next class have had fantastic variety in their markets from all over the globe. It spoke to us that working scientists and students are already envisioning a more sustainable world where biology plays a big role. There are opportunities in pharma, diagnostics and petrochem, but we don’t have to limit ourselves. Open biotech hardware, food, and textiles; practically any consumer market is accessible to Biotech 2.0 companies. Companies that connect directly to consumers will also connect more directly to revenue, making their own money with fewer investments and grants.</p><figure><img alt="" src="https://cdn-images-1.medium.com/max/1024/0*u53lnlah2uQrD5n9.jpg" /></figure><h3>Technology is not Product</h3><p>To scientists, this one sounds counterintuitive. A typical mindset is: “I have a technology that is cheaper than a petrochem company that makes the same thing, so that technology is my product.”</p><p>Engaging customers, knowing what they want and what they pay for, changes a company and its prospects completely. While this approach can work, it is often not the best way to set up a market for a technology. ‘Race to the bottom’ margins, where products are produced more cheaply than traditional processes can turn into losses with a bump in feedstock costs or a drop in oil prices, and investors know this well. A reasonable improvement in product quality can solidify margins of price vs cost and transform a margin cutter into a strong company.</p><figure><img alt="" src="https://cdn-images-1.medium.com/max/1024/0*3nlGibDpdwa1FJYo.jpg" /></figure><h3>Fail Fast</h3><p>This is a key strategy of tech startups, but how does it work with molecular biology? Rather than build a perfect process in R&amp;D and predict the startup trajectory, it is better to create the company holistically. Engaging customers, the scaling processes, defining the product all while doing technology development creates a stronger company in less time.</p><p>Perhaps all of the teams in our program had at least one significant technical plan change, but this is to be expected. Integrated, small-scale experiments performed in parallel with the business plan have brought us to the point where almost the entire class have a working prototype that they can hold in their hands and show to investors.</p><figure><img alt="" src="https://cdn-images-1.medium.com/max/1024/0*-XjrAqPDyw-14zmA.jpg" /></figure><h3>High End Tech does not always mean a better company</h3><p>Sophisticated or cutting edge technology can make a product cheaper, more reliable, or increase performance. But overall, companies with technical plans that were fairly simple did better.</p><p>Simple SynBio projects, such as pathways with just one or two enzymes, already make up the vast majority of successful products in biotech and there is little risk that such a company won’t produce something useful.</p><p>‘Will it work?’ and ‘Will people buy it?’ are questions to ask before ‘How cutting edge is the technology?’</p><figure><img alt="" src="https://cdn-images-1.medium.com/max/1024/0*x4jL5Z_RJrHOtFuq.jpg" /></figure><h3>Translating to investors and customers is a critical skill</h3><p>Learning to communicate to the people you need to work with is vital to gaining access to markets and investment. Having a mentor network in place like the one at IndieBio that includes technical experts, investors, business development and marketing veterans, helps tremendously in getting companies to become much more convincing.</p><p>If I could show the progress in the ability of scientific founders to communicate the value of their product from first week to what we’re seeing now, the differences would be striking!</p><p>This new generation of next generation biotech companies are creating products that are embedded into our everyday lives. There is a good deal more public interest in the field, in no small part because investors can understand the business thoroughly.</p><p>The past few months have shown that biologists can build incredible companies with products that have the potential to change the world the world for the better.</p><h4>Follow us at IndieBio on Twitter: @indbio</h4><p><a href="http://sf.indie.bio/apply-to-sf/">Apply for the Fall 2015 class</a> (early application deadline is June 30th 2015)</p><p>If you’d like to see what our companies have been up to, the <a href="https://www.youtube.com/channel/UCTXxYho9CwbdU9MzjaNu_PQ">live feed of our first class’s Demo Day</a>, will be available on YouTube on June 11 at 3 p.m. Pacific Time</p><p><em>Originally published at </em><a href="http://synbio.plos.org/2015/06/03/indiebio-learning-lessons-and-building-biotech-2-0/"><em>synbio.plos.org</em></a><em> on June 3, 2015.</em></p><img src="https://medium.com/_/stat?event=post.clientViewed&referrerSource=full_rss&postId=553c06378387" width="1" height="1" alt=""><hr><p><a href="https://medium.com/plos-synbio-field-reports/learning-lessons-and-building-biotech-2-0-553c06378387">Learning lessons and building Biotech 2.0</a> was originally published in <a href="https://medium.com/plos-synbio-field-reports">PLOS Synbio Field Reports</a> on Medium, where people are continuing the conversation by highlighting and responding to this story.</p>]]></content:encoded>
        </item>
        <item>
            <title><![CDATA[The #MeetSynbio Campaign]]></title>
            <link>https://medium.com/plos-synbio-field-reports/the-meetsynbio-campaign-4f6151633f7?source=rss----acfecace5654---4</link>
            <guid isPermaLink="false">https://medium.com/p/4f6151633f7</guid>
            <category><![CDATA[synthetic-biology]]></category>
            <category><![CDATA[campaign]]></category>
            <category><![CDATA[science]]></category>
            <dc:creator><![CDATA[Aakriti Jain]]></dc:creator>
            <pubDate>Mon, 27 Jul 2015 15:23:30 GMT</pubDate>
            <atom:updated>2015-07-27T15:23:30.213Z</atom:updated>
            <content:encoded><![CDATA[<figure><img alt="" src="https://cdn-images-1.medium.com/max/1024/1*JN7oPvD6v6BLgXr_FJFBgg.png" /></figure><p>PLOS Synbio is excited to join forces with <a href="http://www.synberc.org/">Synberc</a>, along with <a href="http://igem.org/Main_Page">iGEM</a>, <a href="http://www.aaas.org/pes">AAAS</a>, <a href="http://synbiobeta.com/">Synbiobeta</a>, <a href="http://www.eusynbios.org/">EUSynbioS</a>, and <a href="https://www.thetech.org/">The Tech Museum of Innovation</a> to launch the <a href="http://www.synberc.org/meetsynbio">#MeetSynbio Campaign</a>.</p><p>The motivation behind the campaign is to put a face on synthetic biology. The campaign started with a simple goal: synthetic biologists everywhere tweeting a selfie/picture of themselves in an every day lab situation with a single, 140 character sentence (including the hashtag #meetsynbio) describing their relation to or work in synthetic biology.</p><p>The campaign is for scientists to meet their peers (much like the community we are building here at PLOS Synbio) and open a forum for discussion of mutual interests (scientific or not!) Furthermore, it is an opportunity to seriously come together as a community and talk about the advancement of synthetic biology into a responsible and exciting future.</p><p>Maxx Chatsko from the Motley Fool makes a <a href="http://www.synberc.org/why-meetsynbio">wonderful case</a> for the campaign. In his post, he says,</p><blockquote>The public perception of synthetic biology was an important topic of discussion at the Synberc Spring Retreat at UC Berkeley in early April — and that’s a good thing. Synberc is a major U.S. research program that was created to make biology easier and safer to engineer by encouraging collaboration and educating researchers and policymakers on responsible practices. The organization also engages the public about the risks and benefits of deploying synthetic biology tools. After all, new genetic technologies have great potential to provide a combination of whole and partial solutions to societal issues ranging from climate change to skyrocketing health care expenses that remain completely or partially unaddressed by existing technologies. But that potential may only be realized if the benefits and risks are effectively communicated and discussed with the public.</blockquote><p>In order to amplify the efforts to do exactly that, effectively communicate and discuss the benefits and risks of synthetic biology with not only the public, but also each other, the #meetsynbio campaign was developed.</p><p>There are a lot of exciting events and opportunities for engagement coming up. Check out <a href="http://www.synberc.org/meetsynbio">the #meetsynbio website,</a> or share your work and perceptions of synthetic biology with the community by writing here, at PLOS Synbio!</p><iframe src="https://cdn.embedly.com/widgets/media.html?src=https%3A%2F%2Fwww.youtube.com%2Fembed%2FdGXI8W1DeYk%3Ffeature%3Doembed%26start%3D13%26start%3D13&amp;url=https%3A%2F%2Fwww.youtube.com%2Fwatch%3Ft%3D13%26v%3DdGXI8W1DeYk&amp;image=https%3A%2F%2Fi.ytimg.com%2Fvi%2FdGXI8W1DeYk%2Fhqdefault.jpg&amp;key=d04bfffea46d4aeda930ec88cc64b87c&amp;type=text%2Fhtml&amp;schema=youtube" width="854" height="480" frameborder="0" scrolling="no"><a href="https://medium.com/media/6eb5c55851660f3506ce33be847764e4/href">https://medium.com/media/6eb5c55851660f3506ce33be847764e4/href</a></iframe><blockquote>#MeetSynbio — The People Behind the Science</blockquote><img src="https://medium.com/_/stat?event=post.clientViewed&referrerSource=full_rss&postId=4f6151633f7" width="1" height="1" alt=""><hr><p><a href="https://medium.com/plos-synbio-field-reports/the-meetsynbio-campaign-4f6151633f7">The #MeetSynbio Campaign</a> was originally published in <a href="https://medium.com/plos-synbio-field-reports">PLOS Synbio Field Reports</a> on Medium, where people are continuing the conversation by highlighting and responding to this story.</p>]]></content:encoded>
        </item>
        <item>
            <title><![CDATA[Targeting Genes, More Accurately]]></title>
            <link>https://medium.com/plos-synbio-field-reports/targeting-genes-accurately-e9a3b0eae659?source=rss----acfecace5654---4</link>
            <guid isPermaLink="false">https://medium.com/p/e9a3b0eae659</guid>
            <category><![CDATA[synthetic-biology]]></category>
            <category><![CDATA[crispr]]></category>
            <category><![CDATA[biology]]></category>
            <dc:creator><![CDATA[Aakriti Jain]]></dc:creator>
            <pubDate>Thu, 23 Jul 2015 14:06:52 GMT</pubDate>
            <atom:updated>2015-07-23T14:07:58.175Z</atom:updated>
            <content:encoded><![CDATA[<h4>The CRISPR-Cas9 DNA editing tool is arguably one of the most revolutionary tools in biotechnology, the applications of which range from biofuels to medicine. <strong>Until now, a caveat of the tool was the time and effort spent in finding the perfect guide RNA to target selected genes effectively.</strong></h4><figure><img alt="" src="https://cdn-images-1.medium.com/max/1024/1*5zqmhoR07VZ1Yuig2ohUtw.png" /><figcaption>Infographic on how the CRISPR-Cas9 tool works. Courtesy of the <a href="https://innovativegenomics.org/crispr-cas9-infographic/?utm_content=buffer803f0&amp;utm_medium=social&amp;utm_source=twitter.com&amp;utm_campaign=buffer">Innovative Genomics Institute</a>.</figcaption></figure><p>CRISPR (also known as Clustered Regularly Interspaced Short Palindromic Repeats) and CRISPR-associated (Cas) genes are an essential part of adaptive immunity in an assortment of bacteria and archaea. These organisms use CRISPR-Cas systems to fight off invading genetic material. The CRISPR repeats were actually discovered in the 1980s in <em>E. coli</em>, and in their function was confirmed in 2007 by <a href="http://www.sciencemag.org/content/315/5819/1709">Barrangou et al</a>, in <em>Streptococcus thermophilus</em>, which acquired resistance against bacteriophage by incorporating part of the genome of the infecting virus into its CRISPR locus.</p><p>It wasn’t until 2012 that the potential of this system was realized by <a href="http://www.ncbi.nlm.nih.gov/pubmed/22745249">Doudna and Charpentier</a>. The system required only two components: the Cas9 and a synthetic single guide RNA (sgRNA). The sgRNA programs the Cas9 to attach to DNA, separate the DNA helix, find the correct section of the DNA. The matching sequence needs to be found next to a PAM (or protospacer adjacent motif) sequence in order for the Cas9 protein to lock down and make a double stranded cut in the DNA sequence.</p><p>As with all gene editing tools, the CRISPR-Cas9 system isn’t perfect. A parameter that is often used to assess genome-editing tools is targeting efficiency, or the percentage of desired mutation that is achieved. In general, the targeting efficiency of Cas9 is much better than that of other editing tools, such as ZFNs and TALENs.</p><p>Even though Cas9 is able to precisely carry out genome editing functions, more than one sgRNA can be a possible match for any given gene target. This means that scientists have to spend a considerable amount of time conducting preliminary troubleshooting experiments in order to select the best guide RNA for the given task.</p><p>In order to eliminate some of the trial-and-error process that comes with selecting guide RNAs, a team from the Church lab developed a <a href="http://www.nature.com/nmeth/journal/vaop/ncurrent/full/nmeth.3473.html">predictive software tool</a> that can help find the best sgRNA to direct Cas9 towards the gene targets.</p><iframe src="https://cdn.embedly.com/widgets/media.html?src=https%3A%2F%2Fplayer.vimeo.com%2Fvideo%2F132754303&amp;url=https%3A%2F%2Fvimeo.com%2F132754303&amp;image=http%3A%2F%2Fi.vimeocdn.com%2Fvideo%2F526116490_1280.jpg&amp;key=d04bfffea46d4aeda930ec88cc64b87c&amp;type=text%2Fhtml&amp;schema=vimeo" width="1280" height="720" frameborder="0" scrolling="no"><a href="https://medium.com/media/b11400b2b29ea5804faf0180e520bace/href">https://medium.com/media/b11400b2b29ea5804faf0180e520bace/href</a></iframe><p>The <a href="https://crispr.med.harvard.edu/sgRNAScorer/">software</a> is publicly available for anyone to use and works by hierarchically ranking how effectively any given sgRNA would target the gene in question based on experimental data from human genomes (unlike other comparable algorithms, which work solely based on first principles).</p><blockquote>We started off by asking ourselves, is there something in the guide RNA sequence that could suggest one would work better than others? — Raj Chari, PhD, lead author on study.</blockquote><p>Church’s group conducted a high-throughput study of the activity between 1500 gene targets and their complementary guide RNAs in order to find patterns in the sgRNA sequence that would indicate the effectiveness of binding. By doing this, they were able to find a unique sequence from each gene target, and create a library of all the targets, inserting them into cultured human cells. To test which guide RNAs would be most effective, they inserted the complementary RNAs with Cas9 and conducted genome extraction and sequencing in order to determine which guide RNA was the best match for each target.</p><p>They then used this experimental data to develop the novel algorithm that ranked and scored the most effective guide RNAs for targeting essentially any human gene, even ones that weren’t experimented on in order to develop the software. They were able to do so by identifying unique features in guide RNA sequences that indicated how well they would work for a given gene target.</p><p>Such software can help scientists working with the CRISPR-Cas9 tool to reduce time spent on trial-and-error experiments by narrowing down possible sgRNA sequences and focus on finding creative solutions to larger problems in order to accelerate research in the expansive fields and applications genome editing.</p><img src="https://medium.com/_/stat?event=post.clientViewed&referrerSource=full_rss&postId=e9a3b0eae659" width="1" height="1" alt=""><hr><p><a href="https://medium.com/plos-synbio-field-reports/targeting-genes-accurately-e9a3b0eae659">Targeting Genes, More Accurately</a> was originally published in <a href="https://medium.com/plos-synbio-field-reports">PLOS Synbio Field Reports</a> on Medium, where people are continuing the conversation by highlighting and responding to this story.</p>]]></content:encoded>
        </item>
        <item>
            <title><![CDATA[The National Academy Takes On Science Communication and GMOs]]></title>
            <link>https://medium.com/plos-synbio-field-reports/the-national-academy-takes-on-science-communication-and-gmos-91c4df6c71c1?source=rss----acfecace5654---4</link>
            <guid isPermaLink="false">https://medium.com/p/91c4df6c71c1</guid>
            <category><![CDATA[gmo]]></category>
            <category><![CDATA[science-communication]]></category>
            <dc:creator><![CDATA[David Shifrin]]></dc:creator>
            <pubDate>Tue, 21 Jul 2015 20:26:16 GMT</pubDate>
            <atom:updated>2015-07-21T20:26:16.152Z</atom:updated>
            <content:encoded><![CDATA[<blockquote>How can scientists engage with members of the public to empower decision- making and participation in public policy?</blockquote><p>So asked the National Research Council as the premise for its Roundtable on Public Interfaces of the Life Sciences, held at the beginning of this year.</p><p>The workshop’s relevance for this community comes from its focus on public engagement in the genetically modified organism debate, something of great interest to many synthetic biologists. While the science behind GMOs is well established, opinions on how and where GMOs should be used vary widely, within science and, especially, in society at large. It is an often loud debate that goes much deeper than just the science.</p><p>With that in mind, the NRC, part of the National Academy of Sciences, used the workshop to look at</p><ul><li>How people process scientific information and come to conclusions from it</li><li>External factors that affect how the general public views science</li><li>Culture and politics in GMOs</li></ul><p>These topics, along with a full review of the workshop, were published by National Academies Press in mid-July in a report titled “<a href="http://www.nap.edu/openbook.php?record_id=21750&amp;page=R1">Planning Committee for the Workshop When Science and Citizens Connect: Public Engagement on Genetically Modified Organisms</a>.”</p><h4><strong>Myth-busting: What Science Thinks the Public Thinks</strong></h4><p>Importantly, the workshop didn’t just deal with how scientists can or should communicate their work to the public. Even before this topic was raised, speakers at the workshop spent time pointing out “myths about public perceptions of science.” That is, ideas scientists hold about scientific literacy and social contexts among the public which are not supported by the data. For example, while we often assume that more scientific knowledge leads to more support for science, this is not true. “Increased knowledge was not a driver of public perception […]” in some of the issues that have been studied.</p><p>Another intriguing discussion revolved around the idea that, rather than coordinated efforts by special interest groups that push non-scientific agendas, individuals themselves are largely responsible for the problem. People have internal motivations, often cultural, that lead them to “find information that is consistent with what their group believes.” This occurs regardless of the extent that an individual “thinks like a scientist.” Importantly, one of the speakers pointed out, scientists themselves are heavily biased by their own cultural, ideological or political backgrounds, despite our desire to believe the opposite.</p><p>The third myth discussed was the idea that “the public does not trust scientists.” In fact, public trust and support for science has remained relatively steady for the past 30 years. It is not a lack of trust in science, but — again — a consistent inclination to give more weight to scientists who matched one’s personal cultural/ideological/political/societal context.</p><h4><strong>Emotional Science</strong></h4><p>Not surprisingly, these themes of emotion and cultural context ran throughout the workshop and subsequent report. Speakers looked at the decision-making process and “reality filters” (often expressed as a bias towards thinking one’s ideas are more representative of the norm than they actually are). These are processes that are, of course, affected by an individual’s underlying philosophy — their worldview. Here is what William Hallman from Rutgers said:</p><blockquote>One of the things I often hear from my science colleagues is that the public is certainly just irrational. But I want to assure you that the public is not irrational. They actually do have a basis for their decisions. They are just different from the ones that natural scientists have. (p. 11)</blockquote><p>Hallman also discussed his findings that an early emotional response to something will alter how a person thinks about it later on. This is the opposite of a commonly-presented model where people come to conclusions based on data, which subsequently creates an emotional response. This is especially true for the debate about GMOs, where emotion does seem to have colored peoples’ perspective and either lead them to or work in conjunction with an overestimation of their intellectual understanding of the issue. Hallman again:</p><blockquote>“[People] have not heard very much, they do not know very much, they have never talked about it, they are unaware that they are eating it, and yet they have an opinion.” (p. 12)</blockquote><p>The workshop also looked at the presentation of science and how it fits within “cultural contexts,” the “information climate” made up of the media, entertainment and advertising, and a person’s “individual characteristics.”</p><p>With those ideas, the importance of “framing” a scientific topic become clear. Presenting data must occur within cultural and individual constraints or it will not be recieved. Thinking that the data will speak for itself is a deadly assumption (my words, not the report’s).</p><p>This idea extended into the next topic, which dealt with the politicization of science along with cultural influences. Everything from understanding how science becomes politically charged, to the role of scientists in the political debate about issues like GMOs, to the issue of regulation, was covered in this section.</p><h4><strong>So, What Should Scientists do About it?</strong></h4><p>The last section I want to highlight here is part 5, “How Should Scientists Engage in Conversations about Genetically Modified Organisms?” One major goal suggested by Yale professor Dan Kahan was that</p><blockquote>engaging key stakeholders and ensuring that they know that their concerns are being taken seriously is an important step because others in the community often take their cues from them. (p. 32)</blockquote><p>Furthermore, scientists should engage in communication rather than impose ideas on an audience. This includes being involved with stakeholders who may be on the other side of an issues, or those who are undecided. But it also means understanding how people process information and working within those constraints to present a scientific perspective.</p><p>Scientists can also benefit from learning to tell stories, specifically the “human side” of these issues, and taking advantage of the many communications training resources out there. Again, just putting data out there for public consumption will get us nowhere, whether it’s in regards to GMOs or climate change or anything else. Instead, we have to examine our own biases, acknowledge our own cultural contexts, and interact with the public with humility and respect.</p><p>There is a whole lot more in the 40 page workshop summary, and it’s all worth reading.</p><p>To download a free PDF of <a href="http://www.nap.edu/catalog/21750/public-engagement-on-genetically-modified-organisms-when-science-and-citizens-connect-a-workshop-summary"><em>Public Engagement on Genetically Modified Organisms: When Science and Citizens Connect: A Workshop Summary</em></a>, follow the link and log in with your existing MyNAP account, create a free MyNAP account, or download as a guest.</p><p>In addition, I would encourage you to grab a copy of <a href="http://amzn.to/1Ok6pxh"><em>Communicating Science: Professional, Popular, Literary</em></a><em>”</em> by Nicholas Russell, which deals extensively with many of these same issues.</p><img src="https://medium.com/_/stat?event=post.clientViewed&referrerSource=full_rss&postId=91c4df6c71c1" width="1" height="1" alt=""><hr><p><a href="https://medium.com/plos-synbio-field-reports/the-national-academy-takes-on-science-communication-and-gmos-91c4df6c71c1">The National Academy Takes On Science Communication and GMOs</a> was originally published in <a href="https://medium.com/plos-synbio-field-reports">PLOS Synbio Field Reports</a> on Medium, where people are continuing the conversation by highlighting and responding to this story.</p>]]></content:encoded>
        </item>
        <item>
            <title><![CDATA[PLOS Science Wednesday with Synthetic Biologist, Todd T. Eckdahl]]></title>
            <link>https://medium.com/plos-synbio-field-reports/plos-science-wednesday-with-synthetic-biologist-todd-t-eckdahl-a1642da12b9e?source=rss----acfecace5654---4</link>
            <guid isPermaLink="false">https://medium.com/p/a1642da12b9e</guid>
            <category><![CDATA[reddit]]></category>
            <category><![CDATA[science]]></category>
            <category><![CDATA[synthetic-biology]]></category>
            <dc:creator><![CDATA[Aakriti Jain]]></dc:creator>
            <pubDate>Sun, 19 Jul 2015 20:27:44 GMT</pubDate>
            <atom:updated>2015-07-22T21:12:08.324Z</atom:updated>
            <content:encoded><![CDATA[<h4>On Wed, July 22, 2015, PLOS is hosting Dr. Todd Eckdahl on its weekly PLOS Science Wednesday “Ask Me Anything” (AMA) live chat series on <a href="https://www.reddit.com/r/science/">Reddit science</a>.</h4><h4>UPDATE 7/22 — <a href="https://www.reddit.com/r/science/comments/3e6wb3/plos_science_wednesday_hi_im_dr_todd_eckhadl_here/">here’s the link</a> to Dr. Eckdahl’s just completed AMA. And a sample Q&amp;A:</h4><p><strong>Q:</strong> If I’m understanding this paper correctly, are you suggesting that we could sort of “customize” bacteria to possibly treat illnesses that are related to deficiencies in bacterial functioning in the gut? Are there other places in the body that this is relevant, too? What would this look like in terms of accessibility?</p><p>Thanks for putting this in simple terms for the simple-minded, like me. :)</p><p><a href="https://medium.com/p/a1642da12b9e/edit"><strong>[–]</strong></a><a href="https://www.reddit.com/user/PLOSScienceWednesday"><strong>PLOSScienceWednesda</strong></a><strong>y </strong>I would not call your question simple minded. Knowing about the micro biome (importance of gut bacteria) for our health is pretty sophisticated.</p><p>To answer your question, we never intended the bacteria to go into humans. The goal would be for companies to grow the bacteria in large vats and then purify the medicine for traditional delivery.</p><p><strong>Q: </strong>Oh, the whole time I imagined the conversion would occur inside someones gut . .</p><p><a href="https://medium.com/p/a1642da12b9e/edit"><strong>[–]</strong></a><a href="https://www.reddit.com/user/PLOSScienceWednesday"><strong>PLOSScienceWednesday</strong></a> That could happen down the road, but not until we understand human gut ←&gt; microbe interactions.</p><h4><strong>For more about the paper and the authors, continue with Aakriti Jain’s preview post…</strong></h4><p>Dr. Eckdahl is a Professor and Chairperson at the Department of Biology at Missouri Western State University. His lab is interested in using engineering principles and molecular biology tools to design and construct genetic circuits in living cells; in particular, in constructing bacterial computers that can solve mathematical or biological problems.</p><figure><img alt="" src="https://cdn-images-1.medium.com/max/537/1*3dNAJPZC9JZPNgCvNece_A.jpeg" /></figure><p>The focus of this particular AMA will be his group’s recent publication in <em>PLOS One</em>, titled <a href="http://www.plosone.org/article/Authors/info:doi/10.1371/journal.pone.0118322">“Programmed Evolution for Optimization of Orthogonal Metabolic Output in Bacteria.”</a></p><blockquote><em>The article describes an out-of-the-box approach to applying engineering principles to biology. While typical metabolic engineering suffers from low output levels due to natural selection in the model organism, Eckdahl and his group crafted a methodology that embraces the inherent materials evolution in biological engineering. Their approach, dubbed Programmed Evolution, serves as a proof of concept of a strategy that can be used to optimize metabolic pathways by “inverting the standard paradigm in metabolic engineering by harnessing evolution instead of fighting it.” </em><a href="http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0118322"><em>Read more here</em></a><em>.</em></blockquote><figure><img alt="" src="https://cdn-images-1.medium.com/max/1024/1*X9C5y9i9jSs4D7JgSRcD_g.png" /><figcaption>Fig. 2 from paper. Programmed Evolution. The Combinatorics Module facilitates variation of elements controlling orthogonal metabolism. Genetic variation is illustrated by different colors of bacteria. The Fitness Module defines fitness as orthogonal metabolic output and cell growth, and imposes negative selection on bacteria with low metabolic output, shown by elimination of some of the colored bacteria. A Biosensor Module is used to measure the metabolic output of the population or individual cells. Programmed Evolution can be repeated for successive cycles.</figcaption></figure><p>Dr. Eckdahl is very enthusiastic about involving undergraduates in scientific research, and his lab focuses greatly on incorporating young students in outstanding research projects.</p><h4>About PLOS Science Wednesday</h4><p>If you are not already familiar with Science Wednesday, PLOS, in conjunction with Reddit and their AMA feature, launched a weekly series where you, the reader, can ask our authors anything on <a href="http://www.reddit.com/r/science">/r/science</a>. We created this to showcase new research in the various fields that PLOS publishes in while allowing our authors to directly interact with and answer any questions from fellow researchers and readers. For more information on PLOS Science Wednesdays and archives of previous AMAs, <a href="http://blogs.plos.org/plos/2015/04/plos/">click here</a>.</p><img src="https://medium.com/_/stat?event=post.clientViewed&referrerSource=full_rss&postId=a1642da12b9e" width="1" height="1" alt=""><hr><p><a href="https://medium.com/plos-synbio-field-reports/plos-science-wednesday-with-synthetic-biologist-todd-t-eckdahl-a1642da12b9e">PLOS Science Wednesday with Synthetic Biologist, Todd T. Eckdahl</a> was originally published in <a href="https://medium.com/plos-synbio-field-reports">PLOS Synbio Field Reports</a> on Medium, where people are continuing the conversation by highlighting and responding to this story.</p>]]></content:encoded>
        </item>
        <item>
            <title><![CDATA[Synbio pioneers: Brian Bachmann, Looking Backwards to Move Forward]]></title>
            <link>https://medium.com/plos-synbio-field-reports/synbio-pioneers-brian-bachmann-looking-backwards-to-move-forward-29f35baa1889?source=rss----acfecace5654---4</link>
            <guid isPermaLink="false">https://medium.com/p/29f35baa1889</guid>
            <category><![CDATA[evolution]]></category>
            <category><![CDATA[vanderbilt]]></category>
            <category><![CDATA[synthetic-biology]]></category>
            <dc:creator><![CDATA[David Shifrin]]></dc:creator>
            <pubDate>Fri, 17 Jul 2015 16:34:24 GMT</pubDate>
            <atom:updated>2015-07-17T16:37:48.298Z</atom:updated>
            <content:encoded><![CDATA[<p><em>This article appeared on the original PLOS Synthetic Biology Community in May, 2015</em></p><h4>Starting with the end in mind</h4><p>“Start with the end in mind.” So says businessman and leadership icon <a href="https://www.stephencovey.com/7habits/7habits-habit2.php">Stephen R. Covey</a> in a statement that has permeated modern culture across disciplines. Turns out, it may also be one of the best ways to approach designing biological circuits.</p><p>That, at least, is the idea underpinning Brian Bachmann’s lab at Vanderbilt University. Dr. Bachmann recently sat down with the PLOS Synthetic Biology Community to talk about his background, current work, and thoughts on some of the approaches being tested and used within the synthetic biology field.</p><figure><img alt="" src="https://cdn-images-1.medium.com/max/587/0*3iqKB1N1VHTIQbuj.png" /></figure><p>Brian Bachmann, PhD, Associate Professor of Chemistry; Vanderbilt University</p><h4>Making the decision: academia or industry?</h4><p>Bachmann received his PhD from Johns Hopkins, where he worked on the biosynthesis of beta-lactams and discovered <a href="http://www.ncbi.nlm.nih.gov/pubmed/9689037">beta-lactam synthase</a>. This was in the late ‘90s, and Bachmann was conflicted between a career in academia (which he had fallen in love with) and industry (which was his original plan). Either way, though, he was interested in the connection between genomics and natural products.</p><p>Once a year or so, someone would publish a completed gene cluster for biosynthesis of a natural product. Each paper that came out stimulated deep conversations between Bachmann and his colleagues about the data and consequences.</p><p>In relatively short order, the field reached a point where scientists could begin to predict the structure of products from their gene clusters. Today, he says,</p><blockquote><em>“I think this field is probably the only one where we’ve been able to translate principles to actually predict concrete output of gene sequence data, down to very complex 3D structures including stereochemistry.”</em></blockquote><p>Somewhere around the end of graduate school, Bachmann attended a conference and saw talk by Ecopia Biosciences. “They had developed a technology to very rapidly sequence gene clusters,” which reduced the time it took to sequence a gene cluster from a year or many months to about a week. “I got so excited by the database they had that I couldn’t resist the opportunity to […] go up to Montreal and work for them.” There, Bachmann worked on the genomics of secondary metabolism.</p><h4>Finding opportunities from the crash</h4><p>As with most of the industry, the 2001 tech crash had a dramatic effect on publicly held Ecopia. The company realized that selling genomic data “was not a business model.” A shift took place, and Bachmann was given the assignment of trying to isolate molecules predicted by sequence data. They wanted him to “put your money where your mouth is,” he says, and obtain real substances out of the predictive data he was working on. Bachmann led a group within the company, and they soon reached a point where they were isolated one compound per month.</p><p>It was an exciting time, but Bachmann started thinking a change might be in order.</p><blockquote><em>“I realized that I missed academia. While I found the job very rewarding and stimulating, there were some things that I felt I needed to do scientifically.”</em></blockquote><p>He started looking for academic jobs while continuing to build the team at Ecopia and isolating new molecules. In 2003, Bachmann took a position at Vanderbilt University.</p><blockquote><em>“The reason I got into natural product biosynthesis in the first place was, coming from a synthetic background, an interest in ‘can we do chemical synthesis, total synthesis, within organisms?’ So I came to Vanderbilt specifically to engineer biosynthetic pathways to make non-natural products. The level of risk was really more appropriate for an academic setting.”</em></blockquote><h4>Evolving in the university</h4><p>Today, part of <a href="http://www.vanderbilt.edu/chemistry/faculty/bachmann.php">his lab</a> is continuing this synthetic biology project, working to make non-natural products through biosynthetic pathways.</p><blockquote><em>“My vision was, could we take the lessons learned from reading the blueprints of natural product biosynthesis for twenty years to the point where we could predict accurately what they make? Can we take those lessons and apply them to making new compounds?”</em></blockquote><p>Directed evolution and enzyme engineering play a huge role in this field, and Bachmann came of age scientifically as that work was coming online. In order to make non-natural products out of novel biosynthetic pathways, though, the pathways themselves obviously have to be optimized. Thinking about ways to do this led Bachmann to a position that, well, puts him somewhat at odds with a significant part of the synthetic biology movement.</p><h4>Picking apart parts-based design</h4><blockquote><em>“I decided to focus on aspects of pathway assembly. I decided it was an unsolved problem. There is a big movement in synthetic biology called the ‘parts-device approach.’ We are going to build a toolkit of parts and then assemble them into devices. I believe that is a fundamentally flawed approach when it comes to biosynthetic pathway engineering. Enzymes are remarkably selective for their substrates, and fluxes need to be controlled and engineered in as you build. So it seemed to me that we would not be able to build the equivalent of electrical circuits that create compounds, because of the amount of evolutionary optimization [required for] each part.”</em></blockquote><p>Bachmann believes that this specificity ultimately causes a breakdown in the parts-device method of synthetic biology, to the point where he suggests it should be abandoned.</p><p>Additionally, enzymes are still something of a black box, and scientists still don’t really understand how they work. “We have transition state theory, but that’s not enough. We don’t understand them enough to design them, yet. So I think that for the part-device approach to work, we’re going to need to design catalysts rapidly,” which will include evolutionary and computational technologies. If you have to make a custom part for every component, Bachmann wonders, is the part-device model worth it?</p><h4>Finding an alternative</h4><p>Instead, his group focused on processes derived from evolution. “The thinking based on looking at sequence data is that [biological systems] recruit enzymes from primary metabolism and start to concatenate them,” he says. “The products that are formed create value-added materials that give [the organisms] an evolutionary fitness advantage.” Eventually, over evolution-scale periods of time, pathways are assembled.</p><blockquote><em>“This is the model of what I would say is done in pathway engineering. You have recruitment, sometimes there’s simultaneous recruitment of each enzyme for a given substrate, but ultimately they’re put together in a forward linear fashion to try to get to a product.”</em></blockquote><p>However, this approach didn’t satisfy Bachmann, either. “We decided this was too inefficient for our scale of endeavor.” He went back to his roots in chemical synthesis and looked at a principle called “retrosynthesis,” essentially reverse engineering. And here is where the principles of a world-famous leadership expert converge with evolutionary biology: begin with the end product and work backwards to determine how to build the pathway. “Let’s start with the last step, evolve the last step to make the product from an available precursor and enzyme. Then we’ll go to the penultimate step and evolve that enzyme in the presence of the optimized enzyme, again selecting for product.” And so on, always selecting for product in a process termed “bioretrosynthesis.”</p><p>While problems can arise regardless of which direction you might be working in, Bachmann thinks that retrosynthesis leads to fewer dead ends:</p><blockquote><em>“The number of possibilities starting from the beginning is much, much larger, and the number of branch points is much larger, that could lead to potential dead ends. But if you’re always using that product selection, then you always have your eyes on the prize and you only need one selection method to evolve all these enzymes […] The efficiency is much greater.”</em></blockquote><figure><img alt="" src="https://cdn-images-1.medium.com/max/825/0*fZRsUMlLxdielGgU.jpg" /></figure><p>Darwin and Edison keep a close watch over the evolutionary activies in the Bachmann Lab.</p><h4>Following in the footsteps of an icon</h4><p>Bachmann built his group around testing this model of design and quickly realized that he was late to the party. Norman Horowitz originally developed the idea of bioretrosynthesis at Caltech in the 1940’s as an evolutionary theory, suggesting that it was how biosynthetic pathways actually came about. (For more on the fascinating Norman Horowitz, see his <a href="http://articles.latimes.com/2005/jun/03/local/me-horowitz3">2005 obituary in the <em>LA Times</em></a> and this <a href="http://oralhistories.library.caltech.edu/22/1/OH_Horowitz_N.pdf">interview he did in 1984</a> for Caltech.)</p><p>“Perhaps inadvisably,” Bachmann says with a smile, his group decided to apply principles from Horowitz to an entirely new pathway. The goal? To synthesize nucleoside analogues — completely unnatural products that are used in the pharmaceutical industry as anti-viral reverse transcriptase inhibitors.</p><blockquote><em>“The reason we chose them was because we could imagine using the toolkit that primary metabolism has supplied and adapting it to make them. We also determined that they’re very expensive to make chemically […] due to the high cost of the starting materials.”</em></blockquote><p>However, nucleoside analogues are relatively straightforward to synthesize, only taking a handful of steps. “We thought that if we could make the molecule biosynthetically rather than chemically, we could lower the cost and make it less financially toxic,” he says. “It was worth doing and it was possible.”</p><h4><strong>Validating backwards thinking</strong></h4><p>According to the plan, Bachmann’s group started from the end and worked backwards, with design and optimization each enzyme in the pathway becoming a PhD project. They published a <a href="http://www.ncbi.nlm.nih.gov/pubmed/24657930">paper</a> last year describing the process, which to Bachmann’s knowledge is the first example of a pathway like this being applied to make a compound.</p><figure><img alt="" src="https://cdn-images-1.medium.com/max/913/0*K56QwEQn-i-psDxE.png" /></figure><p>“I was excited to get it out there, I want people to adopt it.” When asked if he thought having the method published and somewhat validated would indeed lead to wider adoption, Bachmann said, “I’ve been getting a lot of good feedback, a lot of buzz. When I talk to people, they say, ‘I’m going to do that!’ So I’m optimistic.”</p><p>However, he points out that not everyone is sold, and he is unsure about how the engineering community will respond.</p><blockquote><em>“There are some disadvantages to the approach, namely, it’s linearly contingent and you can only optimize one enzyme at a time. With the other method, you can evolve all of the enzymes simultaneously.”</em></blockquote><p>Even so, to date there have been very few examples of a successfully engineered pathway built to produce unnatural products. According to Bachmann, “there are lots and lots of pathways for recapitulating natural products, there are biofuel pathways, but for making a totally non-natural compound in a multistep pathway…it’s very rare.”</p><h4>Working the middle ground</h4><p>Taking a broader perspective of the field, Bachmann groups small molecule synthetic biology into three main categories: recapitulation of existing pathways, development of <em>de novo </em>pathways, and “tweaking,” which sits somewhere between the first two. In this last area, researchers take existing pathways and make modifications to produce a desired outcome. In addition to their work in bioretrosynthesis, Bachmann’s group is also interested in the tweaking process, which he points out is far more feasible than creating a pathway <em>de novo</em>.</p><blockquote><em>“The big excitement in that area is that […] with recombinant technologies, we can do SAR [structure-activity relationship] to some extent by changing the gene clusters that encode natural products to make analogues not found in nature. I think the potential of that is huge […] we should be able to generate dozens or hundreds of scaffolds and optimize them as human drugs.”</em></blockquote><p>It seems to be working, and Bachmann’s group has developed analogues to a complex molecule that had previously been pulled from the clinical trial pipeline due to issues of clearance from the body in different populations. The hope, then, is to take something “so close to being a drug” and tweak its biosynthetic pathway to make favorable structural changes that will eliminate the problems. At the same time, the team is gaining deep insight into the enzymology of the natural pathways. Thus, Bachmann points out, the project is also valuable from a basic science standpoint.</p><h4>Looking to the future</h4><p>So where does Bachmann see synthetic biology headed?</p><blockquote><em>“I think the future of the field will be the successful ability to engineer enzymes that do non-natural reactions, which is the holy grail of the field […] I feel strongly that if we can build on chemistry and physics, from the ground up, that that’s the solution to engineering in biological systems. Biological reductionism, on the other hand, does not work. Representing proteins and circles, and reactions as arrows, is not predictive, it’s descriptive. You can’t engineer with it.”</em></blockquote><p>What is exciting for Bachmann, and encouraging for the field as a whole, is that there has been progress in this area. He points to groups designing reasonably functional enzymes and developing better computational modeling systems that help the whole process.</p><p>“They’ll engineer enzymes to do a non-natural reaction, and then they still have to use directed evolution to optimize it.” “But,” he says putting in one final plug for his method of choice, “I still think that doing it retro might have some advantages.” For Bachmann, at least, forward thinking will continue to require looking backwards.</p><p><em>For more on bioretrosynthesis, check out Bachmann’s 2010 review “</em><a href="http://www.nature.com/nchembio/journal/v6/n6/full/nchembio.377.html"><em>Biosynthesis: is it time to go retro?</em></a><em>” in Nature Chemical Biology. Then, let us know what you think in the comments. We’d love to hear your questions and comments on the pros and cons of various pathway engineering methods. So please, jump in!</em></p><img src="https://medium.com/_/stat?event=post.clientViewed&referrerSource=full_rss&postId=29f35baa1889" width="1" height="1" alt=""><hr><p><a href="https://medium.com/plos-synbio-field-reports/synbio-pioneers-brian-bachmann-looking-backwards-to-move-forward-29f35baa1889">Synbio pioneers: Brian Bachmann, Looking Backwards to Move Forward</a> was originally published in <a href="https://medium.com/plos-synbio-field-reports">PLOS Synbio Field Reports</a> on Medium, where people are continuing the conversation by highlighting and responding to this story.</p>]]></content:encoded>
        </item>
    </channel>
</rss>